IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines-Reference-Cited by-同舟云学术

IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines

Published:2022-03-24 Issue:4 Volume:23 Page:532-542
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Tahtinen Siri,Tong Ann-Jay,Himmels Patricia,Oh Jaehak^ORCID,Paler-Martinez Andres,Kim Leesun,Wichner Sara,Oei Yoko,McCarron Mark J.,Freund Emily C.,Amir Zhainib Adel,de la Cruz Cecile C.,Haley Benjamin,Blanchette Craig,Schartner Jill M.,Ye Weilan^ORCID,Yadav Mahesh,Sahin Ugur^ORCID,Delamarre Lélia,Mellman Ira^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

https://www.nature.com/articles/s41590-022-01160-y.pdf

Reference50 articles.

1. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).

2. Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107–112 (2020).

3. Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature 586, 594–599 (2020).

4. Braiteh, F. et al. Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors. Cancer Res. 80 (Suppl.), abstr. CT169 (2020).

5. Lopez, J. S. et al. Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Res. 80 (Suppl.), abstr. CT301 (2020).

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the impact of lipid nanoparticles on protein stability and cellular proteostasis;Journal of Colloid and Interface Science;2025-01

2. Sparsely PEGylated poly(beta-amino ester) polyplexes enhance antigen specific T-cell response of a bivalent SARS-CoV-2 DNA vaccine;Biomaterials;2024-12

3. Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis;Journal of Controlled Release;2024-10

4. The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA;Journal of Controlled Release;2024-10

5. Engineering CaP-Pickering emulsion for enhanced mRNA cancer vaccines via dual DC and NK activations;Journal of Controlled Release;2024-09